← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 4.1% to $36.3M, while Net income decreased 16.4% to ($6.0M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $36.3MWatch
- Profitability — Net income ($6.0M)Watch
- Cash generation — Free cash flow ($5.5M)Note
- Accounting — Formula distress score · no manipulation flag · earnings quality safeWatch
- Insiders — 0 buys; 0 sells in 365 daysNote
- Capital — share repurchases were $0Note
Business
Sunshine Biopharma Inc.: Securities and Exchange Commission SOC Security Operations Center Street Name Securities held in the name of a brokerage firm on behalf of a client Sunshine Canada Sunshine Biopharma Canada Inc., a wholly owned subsidiary of the Company U.S.
Leadership changes
From Sunshine Biopharma Inc.'s own filings, the day they're filed.
- Michel Roy · Chief Commercial Officer · appointmenteff. 2025-01-13
- Malek Chamoun · Chief Development Officer · appointment
- Marc Beaudoin · Chief Operating Officer · appointment
Latest filings
- 8-K · Company announcement2026-08-28
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-07-20
- 8-K · Company announcement2026-07-10
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Sunshine Biopharma Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.